Center-Authored Papers

Filters: Author is Cheng, Heather H  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
2012
Pritchard CC, Cheng HH, Tewari M.  2012.  MicroRNA profiling: approaches and considerations.. Nature reviews. Genetics. 13(5):358-69. Abstract
2013
Cheng HH, Mitchell PS, Kroh EM, Dowell AE, Chéry L, Siddiqui J, Nelson PS, Vessella RL, Knudsen BS, Chinnaiyan AM et al..  2013.  Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia.. PloS one. 8(7):e69239. Abstract
Cheng HH, Yi HS, Kim Y, Kroh EM, Chien JW, Eaton KD, Goodman MT, Tait JF, Tewari M, Pritchard CC.  2013.  Plasma processing conditions substantially influence circulating microRNA biomarker levels.. PloS one. 8(6):e64795. Abstract
Lee FC, Harris W, Cheng HH, Shenoi J, Zhao S, Wang J, Champion T, Izard J, Gore JL, Porter M et al..  2013.  Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer.. Advances in urology. 2013:317190. Abstract
2014
Montgomery B, Cheng HH, Drechsler J, Mostaghel EA.  2014.  Glucocorticoids and prostate cancer treatment: friend or foe? Asian journal of andrology. Abstract
Chevillet JR, Kang Q, Ruf IK, Briggs HA, Vojtech LN, Hughes SM, Cheng HH, Arroyo JD, Meredith EK, Gallichotte EN et al..  2014.  Quantitative and stoichiometric analysis of the microRNA content of exosomes.. Proceedings of the National Academy of Sciences of the United States of America. 111(41):14888-93. Abstract
James AC, Lee FC, Izard JP, Harris WP, Cheng HH, Zhao S, Gore JL, Lin DW, Porter MP, Yu EY et al..  2014.  Role of Maximal Endoscopic Resection Before Cystectomy for Invasive Urothelial Bladder Cancer.. Clinical genitourinary cancer. Abstract
256
Cheng HH, Yi HS, Kim Y, Kroh EM, Chien JW, Eaton KD, Goodman MT, Tait JF, Tewari M, Pritchard CC.  2013.  Plasma processing conditions substantially influence circulating microRNA biomarker levels.. PloS one. 8(6):e64795. Abstract
257
Cheng HH, Yi HS, Kim Y, Kroh EM, Chien JW, Eaton KD, Goodman MT, Tait JF, Tewari M, Pritchard CC.  2013.  Plasma processing conditions substantially influence circulating microRNA biomarker levels.. PloS one. 8(6):e64795. Abstract
258
Cheng HH, Yi HS, Kim Y, Kroh EM, Chien JW, Eaton KD, Goodman MT, Tait JF, Tewari M, Pritchard CC.  2013.  Plasma processing conditions substantially influence circulating microRNA biomarker levels.. PloS one. 8(6):e64795. Abstract
Androgen Antagonists
Cheng HH, Higano CS.  2014.  Targeting the androgen receptor signaling axis to reduce testosterone levels in prostate cancer: how low should we go? Oncology (Williston Park, N.Y.). 28(8):700-1.
April 2014
Montgomery B, Cheng HH, Drechsler J, Mostaghel EA.  2014.  Glucocorticoids and prostate cancer treatment: friend or foe? Asian journal of andrology. Abstract
Center-Authored Paper
Cheng HH, Mitchell PS, Kroh EM, Dowell AE, Chéry L, Siddiqui J, Nelson PS, Vessella RL, Knudsen BS, Chinnaiyan AM et al..  2013.  Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia.. PloS one. 8(7):e69239. Abstract
Clinical Research Division
Lee FC, Harris W, Cheng HH, Shenoi J, Zhao S, Wang J, Champion T, Izard J, Gore JL, Porter M et al..  2013.  Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer.. Advances in urology. 2013:317190. Abstract
Montgomery B, Cheng HH, Drechsler J, Mostaghel EA.  2014.  Glucocorticoids and prostate cancer treatment: friend or foe? Asian journal of andrology. Abstract
James AC, Lee FC, Izard JP, Harris WP, Cheng HH, Zhao S, Gore JL, Lin DW, Porter MP, Yu EY et al..  2014.  Role of Maximal Endoscopic Resection Before Cystectomy for Invasive Urothelial Bladder Cancer.. Clinical genitourinary cancer. Abstract
Cheng HH, Lin DW, Yu EY.  2012.  Advanced clinical States in prostate cancer.. The Urologic clinics of North America. 39(4):561-71. Abstract
Pritchard CC, Cheng HH, Tewari M.  2012.  MicroRNA profiling: approaches and considerations.. Nature reviews. Genetics. 13(5):358-69. Abstract
Cheng HH, Mitchell PS, Kroh EM, Dowell AE, Chéry L, Siddiqui J, Nelson PS, Vessella RL, Knudsen BS, Chinnaiyan AM et al..  2013.  Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia.. PloS one. 8(7):e69239. Abstract
Electron Microscopy Core Facility
Chevillet JR, Kang Q, Ruf IK, Briggs HA, Vojtech LN, Hughes SM, Cheng HH, Arroyo JD, Meredith EK, Gallichotte EN et al..  2014.  Quantitative and stoichiometric analysis of the microRNA content of exosomes.. Proceedings of the National Academy of Sciences of the United States of America. 111(41):14888-93. Abstract
Genomics Core Facility
Cheng HH, Mitchell PS, Kroh EM, Dowell AE, Chéry L, Siddiqui J, Nelson PS, Vessella RL, Knudsen BS, Chinnaiyan AM et al..  2013.  Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia.. PloS one. 8(7):e69239. Abstract
Chevillet JR, Kang Q, Ruf IK, Briggs HA, Vojtech LN, Hughes SM, Cheng HH, Arroyo JD, Meredith EK, Gallichotte EN et al..  2014.  Quantitative and stoichiometric analysis of the microRNA content of exosomes.. Proceedings of the National Academy of Sciences of the United States of America. 111(41):14888-93. Abstract
Human Biology Division
Pritchard CC, Cheng HH, Tewari M.  2012.  MicroRNA profiling: approaches and considerations.. Nature reviews. Genetics. 13(5):358-69. Abstract
Cheng HH, Mitchell PS, Kroh EM, Dowell AE, Chéry L, Siddiqui J, Nelson PS, Vessella RL, Knudsen BS, Chinnaiyan AM et al..  2013.  Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia.. PloS one. 8(7):e69239. Abstract
Humans
Cheng HH, Higano CS.  2014.  Targeting the androgen receptor signaling axis to reduce testosterone levels in prostate cancer: how low should we go? Oncology (Williston Park, N.Y.). 28(8):700-1.